Literature DB >> 32728946

An atlas on risk factors for multiple sclerosis: a Mendelian randomization study.

Shuai Yuan1, Ying Xiong2, Susanna C Larsson3,4.   

Abstract

OBJECTIVES: We conducted a systematic review and wide-angled Mendelian randomization (MR) study to examine the association between possible risk factors and multiple sclerosis (MS).
METHODS: We used MR analysis to assess the associations between 65 possible risk factors and MS using data from a genome-wide association study including 14 498 cases and 24 091 controls of European ancestry. For 18 exposures not suitable for MR analysis, we conducted a systematic review to obtain the latest meta-analyses evidence on their associations with MS.
RESULTS: Childhood and adulthood body mass index were positively associated with MS, whereas physical activity and serum 25-hydroxyvitamin D were inversely associated with MS. There was evidence of possible associations of type 2 diabetes, waist circumference, body fat percentage, age of puberty and high-density lipoprotein cholesterol. Data of systematic review showed that exposure to organic solvents, Epstein Barr virus and cytomegalovirus virus infection, and diphtheria and tetanus vaccination were associated with MS risk.
CONCLUSIONS: This study identified several modifiable risk factors for primary prevention of MS that should inform public health policy.

Entities:  

Keywords:  Mendelian randomization; Multiple sclerosis; Prevention strategy; Risk factors

Mesh:

Year:  2020        PMID: 32728946      PMCID: PMC7815542          DOI: 10.1007/s00415-020-10119-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  1 in total

1.  Total intake of different minerals and the risk of multiple sclerosis.

Authors:  Marianna Cortese; Tanuja Chitnis; Alberto Ascherio; Kassandra L Munger
Journal:  Neurology       Date:  2019-04-03       Impact factor: 9.910

  1 in total
  9 in total

Review 1.  Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.

Authors:  Marijne Vandebergh; Nicolas Degryse; Bénédicte Dubois; An Goris
Journal:  J Neurol       Date:  2022-04-02       Impact factor: 6.682

2.  The Effect of Peripheral Immune Cell Counts on the Risk of Multiple Sclerosis: A Mendelian Randomization Study.

Authors:  Di He; Liyang Liu; Dongchao Shen; Peng Zou; Liying Cui
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

3.  Circulating Interleukins and Risk of Multiple Sclerosis: A Mendelian Randomization Study.

Authors:  Hui Lu; Peng-Fei Wu; Wan Zhang; Xiaoyao Liao
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

4.  Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies.

Authors:  Susanna C Larsson; Stephen Burgess
Journal:  BMC Med       Date:  2021-12-15       Impact factor: 8.775

5.  Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis: A Mendelian Randomization Study.

Authors:  Marijne Vandebergh; Bénédicte Dubois; An Goris
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-04-07

Review 6.  Sex-Specific Environmental Impacts on Initiation and Progression of Multiple Sclerosis.

Authors:  Jonatan Leffler; Stephanie Trend; Shelley Gorman; Prue H Hart
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

7.  Body Mass Index, Interleukin-6 Signaling and Multiple Sclerosis: A Mendelian Randomization Study.

Authors:  Marijne Vandebergh; Sara Becelaere; Bénédicte Dubois; An Goris
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

Review 8.  Epstein-Barr virus and multiple sclerosis.

Authors:  Samantha S Soldan; Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2022-08-05       Impact factor: 78.297

9.  Physical activity and risk of multiple sclerosis: A Mendelian randomization study.

Authors:  Chunyu Li; Junyu Lin; Tianmi Yang; Yi Xiao; Qirui Jiang; Huifang Shang
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.